LAG3 and classic Hodgkin lymphoma: LAG-3 was proposed as a candidate for combination therapy with PD-1 blockade in adult cHL to restore T-cell function more efficiently than either one alone (30), whereas in pediatric patients, the scenario is quite unexplored.